Compare HURA & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HURA | NRO |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 186.3M |
| IPO Year | 2010 | 2003 |
| Metric | HURA | NRO |
|---|---|---|
| Price | $2.16 | $2.55 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.04 | N/A |
| AVG Volume (30 Days) | ★ 250.0K | 222.3K |
| Earning Date | 11-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $2.48 |
| 52 Week High | $3.43 | $3.23 |
| Indicator | HURA | NRO |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 40.70 |
| Support Level | $2.06 | $2.49 |
| Resistance Level | $2.22 | $2.61 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 92.86 | 46.19 |
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").